• JCR Pharmaceuticals received conditional marketing authorization in Kuwait for Izcargo, its blood-brain barrier-penetrating enzyme replacement therapy for Hunter syndrome.
• Kuwait is the second market outside Japan to authorize the treatment, following the United Arab Emirates in July 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JCR Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610141343BIZWIRE_USPR_____20261014_BW154848) on October 14, 2026, and is solely responsible for the information contained therein.